{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:46:19Z","timestamp":1770479179904,"version":"3.49.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1999,6,1]]},"abstract":"<jats:p>OBJECTIVE: To study the effects of GH treatment for up to 42 months on bone mineral density (BMD) and bone turnover. DESIGN AND METHODS: BMD with dual energy X-ray absorptiometry, serum type I procollagen carboxy-terminal propeptide (PICP), serum type I collagen carboxy-terminal telopeptide (ICTP) and serum IGF-I were assessed in 71 adults with GH deficiency. There were 44 men and 27 women, aged 20 to 59 (median 43) years. Thirty-two patients completed 36 months and 20 patients 42 months of treatment. RESULTS: The BMD increased for up to 30-36 months and plateaued thereafter. In the whole study group, the maximum increase of BMD was 5.0% in the lumbar spine (P&lt;0. 001), 5.9% (P&lt;0.01) in the femoral neck, 4.9% (NS, P&gt;0.05) in the Ward's triangle and 8.2% (P&lt;0.001) in the trochanter area. The serum concentrations of PICP (202.6+\/-11.5 vs 116.3+\/-5.4 microg\/l; mean+\/-s.e.m.) and ICTP (10.5+\/-0.6 vs 4.4+\/-0.3 microg\/l) doubled (P&lt;0.001) during the first 6 months of GH treatment but returned to baseline by the end of the study (130.0+\/-10.4 and 5.6+\/-0.7 microg\/l respectively), despite constantly elevated serum IGF-I levels (39. 6+\/-4.1 nmol\/l at 42 months vs 11.9+\/-0.9 nmol\/l at baseline; P&lt;0.001). The responses to GH treatment of serum IGF-I, PICP, ICTP (P&lt;0.001 for all; ANOVA) and of the BMD in the lumbar spine (P&lt;0.05), in the femoral neck and the trochanter (P&lt;0.001 for both) were more marked in men than in women. At the end of the study the BMD had increased at the four measurement sites by 5.7-10.6% (P&lt;0.01-0.001) in patients with at least osteopenia at baseline and by 0.1-5.3% (NS P&lt;0.05) in those with normal bone status (P&lt;0.001 for differences between groups; ANOVA). Among patients who completed 36-42 months of treatment, the number of those with at least osteopenia was reduced to more than a half. The response of BMD to GH treatment was more marked in young than in old patients at three measurement sites (P&lt;0. 05-&lt;0.001; ANOVA). In the multiple regression analysis the gender and the pretreatment bone mass appeared to be independent predictors of three measurement sites, whereas the age independently determined only the vertebral BMD. CONCLUSIONS: GH treatment in GH-deficient adults increased BMD for up to 30-36 months, with a plateau thereafter. Concurrently with the plateau in BMD the bone turnover rate normalized. From the skeletal point of view GH-deficient patients exhibiting osteopenia or osteoporosis should be considered as candidates for GH supplementation of at least 3-4 years.<\/jats:p>","DOI":"10.1530\/eje.0.1400545","type":"journal-article","created":{"date-parts":[[2006,4,14]],"date-time":"2006-04-14T17:39:32Z","timestamp":1145036372000},"page":"545-554","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":57,"title":["Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults"],"prefix":"10.1093","author":[{"given":"MJ","family":"Valimaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PI","family":"Salmela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Salmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Viikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Kataja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Turunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Soppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/140\/6\/545.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/140\/6\/545.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:26:55Z","timestamp":1676392015000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/140\/6\/545\/6755339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,6,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1530\/eje.0.1400545","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,6,1]]}}}